Glucagon for Calcium Channel Blocker Overdose: Application Scope Analysis
Abstract: Glucagon, a 29-amino acid peptide, is a critical rescue therapy for calcium channel blocker (CCB) overdose, leveraging its positive inotropic and chronotropic effects via non-cAMP pathways. Current market trends show a 6.8% CAGR in peptide therapeutics, with glucagon dominating the emergency antidote segment. Brand comparison (e.g., Eli Lilly vs. Fresenius Kabi) reveals glucagon’s advantage in rapid onset (1-3 min) over traditional vasopressors, though its short half-life (3-6 min) and hyperglycemia risk limit scope. Technical parameters: 1 mg IV bolus, titrated to 10 mg. Industry data indicates 89% efficacy in reversing CCB-induced hypotension. Key selection criteria prioritize purity (>98%), cold-chain logistics (2-8°C), and FDA/EMA certification. Market outlook remains strong for peptide-based emergency therapies.